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Chronic lymphocytic leukemia (CLL) displays remarkable clinical heterogeneity, likely 52 
attributed to the underlying biological diversity(1). This claim is supported by the fact 53 
that certain immunogenetic and/or genomic features identify subgroups of CLL 54 
patients with distinct prognosis and outcome(2-4). Indeed, determination of the 55 
somatic hypermutation (SHM) status of the immunoglobulin heavy variable (IGHV) 56 
genes expressed by the clonotypic B cell receptor (BcR) and screening for 57 
aberrations οf the TP53 gene are nowadays considered essential for clinical decision 58 
making(5). A cautionary note appears warranted when utilizing biomarkers, where 59 
the prognosis is usually assessed assuming stable predictability over the disease 60 
course; this hypothesis, however, is often unrealistic as it concerns genomic 61 
aberrations(6, 7). Therefore, arguably, the prognostic power of a given biomarker 62 
may, instead, heavily depend on the time distance from diagnosis. 63 
To address this issue we investigated in early-stage CLL patients the impact over-64 
time of SHM within the IGHV genes, i.e. the segregation into mutated (M-CLL) and 65 
unmutated CLL (U-CLL), on the evolution of risk for CLL progression and need of 66 
treatment. Our analysis was based on hazard curves instead of Kaplan–Meier 67 
survival curves, which represent, respectively, the “instant” risk for the event at each 68 
time-point instead of the cumulative risk(8, 9).  69 
Overall, 1900 early-stage, Binet A CLL patients from 10 European institutions 70 
diagnosed according to the 2008 iwCLL criteria(10) were included in this 71 
retrospective study (summary of patient characteristics: Supplemental Table 1). 72 
Ethical approval was granted by the local review committees and informed consent 73 
was collected according to the Helsinki Declaration. 74 
Fluorescence in situ hybridization (FISH) was performed in 1476/1900 (77.7%) 75 
cases using probes for the 13q14, 11q22, 17p13 regions and trisomy 12; results 76 
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were interpreted following Döhner’s hierarchical model(11). Genes analyzed for 77 
mutations included TP53 (exons 4-10, n=1186/1900, 62.4%), SF3B1 (exons 14-16, 78 
n=1166/1900, 61.4%) and NOTCH1 (entire exon 34 or targeted analysis for del7544-79 
45/p.P2514Rfs*4, n=1691/1900, 89%). Sequence analysis of IGHV/IGHD/IGHJ 80 
rearrangements was performed in all cases as described(12). All FISH, gene 81 
mutation screens and IG gene sequencing studies were performed once before the 82 
administration of any treatment; in 1702/1900 (90%) cases, these tests were 83 
performed within the first year from diagnosis. 84 
In order to assess the risk for disease progression, we evaluated the time-to-first-85 
treatment (TTFT) from diagnosis within different genomic subgroups, with risk 86 
evolution over-time represented by a hazard curve. Smoothed estimates of the 87 
hazard curve were computed separately for M-CLL and U-CLL, based on a non-88 
parametric methodology (“bshazard” package)(13).  89 
To compare the evolution pattern of hazard curves for each subgroup, we 90 
investigated over-time both their differences and ratios. Years 5, 10 and 15 after 91 
diagnosis were considered as landmark time-points for over-time comparison. The 92 
distributions of hazard differences were statistically compared between consecutive 93 
5-year intervals to assess the evolution over-time (trend) of the distance between the 94 
hazard curves of the M-CLL and U-CLL patients. P-values less than 0.05 might 95 
indicate convergence or divergence of the curves within consecutive 5-year intervals. 96 
Regarding the hazard ratios for M-CLL and U-CLL, the proportional hazards 97 
assumption was checked. Moreover, a method able to identify the break points in the 98 
hazard was applied (“RPEXE.RPEXT” package)(14). The analysis was performed 99 
with R. Details about the statistical methodology are provided in Supplemental 100 
Material. 101 
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Based on the SHM status, 1224 (64.4%) and 676 (35.6%) patients were classified as 102 
M-CLL and U-CLL, respectively. The over-time risk for evolution was evaluated with 103 
SHM status as a reference using hazard plots in: (i) the entire cohort, (ii) cases with 104 
TP53 aberrations (TP53abn: del(17p) and/or TP53 mutations), (iii) cases carrying 105 
del(11q) with no TP53abn (del(11q), non TP53abn)), (iv) cases carrying +12 with no 106 
TP53abn (+12, nonTP53abn), (v) cases carrying isolated del(13q) or normal FISH 107 
according to the Döhner model(11) (del(13q)/normal FISH), (vi) NOTCH1 mutations, 108 
and (vii) SF3B1 mutations. 109 
In both the entire cohort and TP53abn patients, M-CLL exhibited gradual risk 110 
decrease over-time (Figure 1B,1D). In contrast, in U-CLL, a constant decrease was 111 
observed in the entire cohort, while in TP53abn cases the hazard curve initially 112 
decreased until the fifth year and then started to increase, indicating intensification of 113 
the risk for progression after the fifth year (Figure 1B,1D). Notably, the survival plots 114 
(Figure 1A,1C) failed to highlight any difference regarding the over-time risk between 115 
M-CLL and U-CLL and exhibited a similar behavior with slowly increasing distance 116 
between the M-CLL and U-CLL survival curves over-time. 117 
In the remaining cases (Supplemental Figures 1-5), the M-CLL hazard curve slowly 118 
decreased except for del(11q) patients. In U-CLL, there was a wide range for hazard 119 
evolution: from decrease, such as for patients with del(13q)/normal FISH), del(11q), 120 
and NOTCH1 mutations; to almost stable hazard over-time (SF3B1 mutant patients). 121 
Interestingly, +12 patients showed a risk evolution similar to cases with TP53abn.  122 
Regarding the distribution of hazard differences, significant differences were found in 123 
the entire cohort between M-CLL and U-CLL in all consecutive pairs of five-year 124 
intervals with p[0,5]Vs(5,10]=0.006, p(5,10]Vs(10,15]=0.009, and p(10,15]Vs(15,20]=0.009 125 
(Supplemental Figure 7A) reflecting a statistically significant decrease of the distance 126 
6 
between the two hazard curves in all pairwise comparisons. The same evolution rule 127 
was followed by the del(13q)/normal-FISH patients as well as patients carrying 128 
del(11q) or  NOTCH1 mutations (Supplemental Figures 7D,7B,7E). For patients with 129 
SF3B1 mutations, the distance between the two curves remained almost stable, 130 
p[0,5]Vs(5,10]=0.465 (Supplemental Figure 7F). In sharp contrast, within TP53abn 131 
patients, the distance between the hazard curves for M-CLL and U-CLL increased 132 
significantly after the 5th year with p[0,5]Vs(5,10]=0.006 (Figure 2A). Similarly, in +12 133 
patients, the U-CLL hazard curve constantly increased from diagnosis, with 134 
p[0,5]Vs(5,10]=0.006 (Supplemental Figure 7C).  135 
Next, we tested the proportional hazards assumption (see Supplemental Table 2, 136 
Supplemental Figure 9) to test whether the hazard ratio between an U-CLL and an 137 
M-CLL patient depended on time. The assumption was rejected only for the 138 
TP53abn patients (p-value=0.045), reflecting the great variation observed with 139 
hazard ratios ranging from 1.75 to 8.09.  140 
We then introduced a novel tool to visualize the comparison of risk evolution 141 
between M-CLL and U-CLL patients, per subgroup, in terms of both the hazard 142 
differences and ratios. A characteristic example concerns TP53abn patients (Figure 143 
2B), where the hazard ratio of U-CLL to M-CLL increased linearly before and 144 
exponentially after the 5th year. Moreover, amongst TP53abn cases, both the 145 
differences and the ratios exhibited the most pronounced change of all the 146 
subgroups considered with ranges 0.22 and 6.33, respectively. TP53abn and +12 147 
patients (Supplemental Figure 8C) were the only subgroups where both the 148 
differences and the ratios increased monotonically over-time, reflecting the 149 
divergence of the hazard curves. By applying piecewise exponential distribution no  150 
breakpoints were observed. 151 
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The concept of hazard curves(15) has not been yet explored in CLL. The principal 152 
advantage of a hazard curve compared to the standard Kaplan-Meier survival curve 153 
is that it represents the “instant” risk for the event of interest at each time-point, 154 
instead of the cumulative risk until that point. This might prove important in CLL, 155 
where, typically, the prognostic power of any biomarker is assumed stable over the 156 
disease course, although this is often unrealistic concerning genomic aberrations. 157 
Hence, it is crucial to evaluate the temporal effect on the factors’ prognostic power 158 
regarding CLL progression. 159 
Our approach was grounded on the fundamental segregation of CLL patients into M-160 
CLL and U-CLL, since the SHM status remains stable over-time(1); furthermore, M-161 
CLL and U-CLL have distinct biological background underlying distinct clonal 162 
behavior and eventual outcome(1, 12). Within each subgroup we assessed how time 163 
distance from diagnosis impacted the prognostic power of several biomarkers on 164 
CLL progression. Taking a step further, we proposed a new method to statistically 165 
evaluate the differences in risk evolution between these patient groups.  166 
In M-CLL, the risk for disease evolution was rather homogeneous across different 167 
genomic subgroups, tending to gradually decrease over-time. In contrast, within U-168 
CLL the pattern of over-time risk evolution was remarkably heterogeneous, greatly 169 
affected by the genomic background of the malignant clone. In particular, TP53abn 170 
cases exhibited a significant increase of disease evolution especially after the 5th 171 
year from diagnosis (further highlighted by the rejection of the proportional hazards 172 
assumption). A similar pattern was observed in +12 cases. A possible explanation for 173 
the hazard increase amongst U-CLL cases with TP53abn and +12 may relate to 174 
either the expansion of the clonal size over-time or the acquisition of extra genomic 175 
abrnormalities, reflecting potential genomic instability.   176 
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In conclusion, differential patterns of risk evolution for disease progression in M-CLL 177 
versus U-CLL support the notion that the SHM status represents more than a simple 178 
prognostic/predictive marker, and that segregation of CLL patients based on SHM 179 
might aid to detect important time effects on risk evolution within genomic subgroups 180 
of CLL patients. Moreover, they imply that specific genomic abnormalities may be 181 
linked to differential risk for disease progression over-time, while their prognostic 182 
impact may be modulated with the time elapsing from the initial diagnosis. This new 183 
methodology for evaluating and visualizing the over-time risk for disease evolution in 184 
CLL is easy to apply and can be generalized to cover the case of scoring systems 185 
where the number of categories compared is more than two, arguably also in other 186 
disease contexts. 187 
188 
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FIGURE LEGENDS 246 
 247 
Figure 1: Standard Kaplan-Meier survival plot and hazard plot for the entire 248 
cohort and the TP53abn patients. The hazard plot shows the estimated proportion 249 
of patients who received treatment for the first time in a defined time interval, given 250 
that they were still treatment-free at the start of this interval. The p-value 251 
corresponding to the log-rank test for the comparison of the survival distributions is 252 
displayed in the survival plot. The table including the number of patients at risk, and 253 
the cumulative number of events/censoring, applies in both plots. For both 254 
subgroups, the survival curves (Figure 1A, 1C) exhibited a similar behavior. When 255 
considering the hazard curves (Figure 1B, 1D), M-CLL showed a gradual decrease 256 
in both subgroups, while U-CLL exhibited significant differences over-time with a 257 
constant decrease over-time in the entire cohort (Figure 1B) and initial decrease until 258 
the fifth year and sudden increase for the TP53abn patients (Figure 1D). 259 
 260 
Figure 2: Hazard plot and evolution of hazard differences/ratios for the 261 
TP53abn patients. 2A: The hazard plot shows the estimated proportion of patients 262 
who received treatment for the first time in a defined time interval, given that they 263 
were still treatment-free at the start of this interval. The hazard differences between 264 
the M-CLL and U-CLL curves are represented by vertical dashed lines. The p-values 265 
of the comparison within consecutive 5-year intervals of the distributions of hazard 266 
differences between M-CLL and U-CLL are also displayed. 2B: The evolution of the 267 
hazard difference, U-CLL – M-CLL, with its scale displayed in the left vertical axis in 268 
red, and the evolution of the hazard ratio, U-CLL/M-CLL, with its scale displayed in 269 
the right vertical axis in black, are simultaneously displayed for all subgroups 270 
considered.  271 
